Sage Therapeutics (SAGE)
(Delayed Data from NSDQ)
$13.28 USD
-0.66 (-4.73%)
Updated May 1, 2024 04:00 PM ET
After-Market: $13.24 -0.04 (-0.30%) 7:58 PM ET
3-Hold of 5 3
F Value B Growth F Momentum F VGM
Brokerage Reports
Sage Therapeutics, Inc. [SAGE]
Reports for Purchase
Showing records 21 - 40 ( 152 total )
Company: Sage Therapeutics, Inc.
Industry: Medical - Drugs
The Future for Zuranolone in MDD Seems Uncertain; Adjusting PT to $27; Reit. Neutral
Provider: H.C. Wainwright & Co., Inc.
Analyst: TSAO D
Company: Sage Therapeutics, Inc.
Industry: Medical - Drugs
Biotechnology- Moving To Neutral On SAGE; Drug Approvals Don''''t Normally Give You The Blues
Provider: Wedbush Securities Inc.
Analyst: CHICO L
Company: Sage Therapeutics, Inc.
Industry: Medical - Drugs
Approval in Postpartum Depression Still Leaves Sage Short After CRL in MDD; Reiterate Neutral
Provider: H.C. Wainwright & Co., Inc.
Analyst: TSAO D
Company: Sage Therapeutics, Inc.
Industry: Medical - Drugs
Company: Sage Therapeutics, Inc.
Industry: Medical - Drugs
Company: Sage Therapeutics, Inc.
Industry: Medical - Drugs
Company: Sage Therapeutics, Inc.
Industry: Medical - Drugs
Company: Sage Therapeutics, Inc.
Industry: Medical - Drugs
Takeaways From Our Conversation with Sage Therapeutics Management
Provider: H.C. Wainwright & Co., Inc.
Analyst: TSAO D
Company: Sage Therapeutics, Inc.
Industry: Medical - Drugs
Takeaways from Company Presentations at Tremor Congress 2023
Provider: H.C. Wainwright & Co., Inc.
Analyst: TSAO D
Company: Sage Therapeutics, Inc.
Industry: Medical - Drugs
Company: Sage Therapeutics, Inc.
Industry: Medical - Drugs
Pre-Launch Activities Escalate Ahead of August 5 PDUFA for Zuranolone; Maintain Neutral
Provider: H.C. Wainwright & Co., Inc.
Analyst: TSAO D
Company: Sage Therapeutics, Inc.
Industry: Medical - Drugs
Company: Sage Therapeutics, Inc.
Industry: Medical - Drugs
Company: Sage Therapeutics, Inc.
Industry: Medical - Drugs
FDA accepts NDA for Zuranolone but More Data Might be Needed; Reiterate Neutral
Provider: H.C. Wainwright & Co., Inc.
Analyst: TSAO D
Company: Sage Therapeutics, Inc.
Industry: Medical - Drugs
All Cylinders Firing As Zuranolone Review Continues [4Q22 SAGE Takeaways]
Provider: Wedbush Securities Inc.
Analyst: CHICO L
Company: Sage Therapeutics, Inc.
Industry: Medical - Drugs
Zuranolone Zipping Along As FDA Accepts Filing, Grants Priority Review
Provider: Wedbush Securities Inc.
Analyst: CHICO L
Company: Sage Therapeutics, Inc.
Industry: Medical - Drugs
Rolling NDA Submission For Zuranolone is Completed
Provider: H.C. Wainwright & Co., Inc.
Analyst: TSAO D
Company: Sage Therapeutics, Inc.
Industry: Medical - Drugs
Zuranolone Filing Nears Finish Line; Reiterate Neutral; Price Target Down to $50
Provider: H.C. Wainwright & Co., Inc.
Analyst: TSAO D
Company: Sage Therapeutics, Inc.
Industry: Medical - Drugs
With Zuranolone On Track, 2023 Will Be Regulatory Focused
Provider: Wedbush Securities Inc.
Analyst: CHICO L